XI'AN, China, July 22 /PRNewswire-Asia-FirstCall/ -- Huifeng Bio-Pharmaceutical Technology, Inc. (OTC Bulletin Board:HFGB), specializing in developing and producing botanical extracts and other raw materials for pharmaceuticals and food additives, today announced the receipt of its European order for approximately 80 metric tons of Diosmin from Galenicum Health S.L.,
Jing'an Wang, the Company's CEO, stated, "I am excited to share news of this purchase order with our investors. HFGB is the only pharmaceutical company in China which has obtained GMP certification and applied for the Certification of Suitability to Monograph of European Pharmacopoeia ("COS") from the European Directorate for the quality of medicine. We currently have customers throughout the world, including France, Japan, South Korea, Australia, Southeast Asia, Russia, India, Germany and the U.S. Once the Company receives COS approval, we believe that the Company will continue to expand its global market share."
Diosmin is a flavonoid that can be isolated from various plant sources or derived from the flavonoid hesperidin. Diosmin is used as a pharmaceutical material as a supplement to treat chronic venous insufficiency, hemorrhoids, lymphedema, and varicose veins.
About Huifeng Bio-Pharmaceutical Technology, Inc.
Huifeng Bio-Pharmaceutical Technology, Inc., located in Xi'an, People's Republic of China, develops and produces plant extracts and pharmaceutical raw materials for use in pharmaceutical, nutraceutical and food production. It is the leading Chinese producer of rutin and related plant-derived chemicals in a class called flavonoids, with medicinal and other beneficial properties. Founded in 2002, Huifeng uses proprietary patented processes to extract rutin more efficiently than traditional extraction techniques. The Company is diversifying its product lines through internal development, acquisition and cooperation with scientific research organizations. More information can be found on the company's web site at: http://www.hfgb.cn/
This press release includes "forward-looking statements" as defined by the Securities and Exchange Commission (the "SEC"), including statements regarding COS certification and shipments of products. All statements, other than statements of historical fact, included in the press release that address activities, events or developments that the company believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors the company believes are appropriate under the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the company and may not materialize, including the timeline for COS approval, receipt of COS approval, delays in manufacturing or transporting product. Investors are cautioned that any such statements are not guarantees of future performance.
For more information, please contact: Investor Relations: Capital Group Communications, Inc. Mr. Kevin Fickle Tel: +1-925-330-8315 Email: Kevin@capitalgc.com Company Contact: Huifeng Bio-Pharmaceutical Technology, Inc. Mr. Steven Tong, IR Director Tel: +86-135-721-18351 Email: Steven@xahuifeng.com
SOURCE Huifeng Bio-Pharmaceutical Technology, Inc.
Subscribe to our Free Newsletters!
Neuroblastoma is a very rare type of childhood cancer that develops in immature nerve cells ...
Video-electroencephalography monitoring is a diagnostic technique that records the electrical ...
Myomectomy is a surgery that is done to remove fibroids, which are non-cancerous growths of the ...View All